Agreed,
I can't deny it, there is more risk compared to a year ago from the funding side....and yes, it's getting a little too close to the flame...I doubt we will have funds to last till the end of the P3....BUT, despite that, I know there are viable alternatives to another round of dilutive CR...in fact I'm pretty confident we won't be having another of those any time soon! Let's avoid that oblivion type scenario.
I'll have more to say about it on the weekend...
Just catching up on some work but will post more soon.
Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial, page-23
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.0¢ | $133.5K | 564.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 108916 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 58538 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 24.0¢ | 23.5¢ | 80791 | ||
| Last updated 15.54pm 17/06/2024 ? | |||||
| PAR (ASX) Chart |
